Form 4: MAIA Director Acquires 24,633 Stock Options

MAIA Biotechnology Director Steven M. Chaouki acquired 24,633 stock options with an exercise price of $1.53, vesting immediately.

Summary

• Steven M. Chaouki, a Director of MAIA Biotechnology, Inc. (MAIA), acquired 24,633 stock options.
• The options were granted on December 31, 2025, under the company's 2021 Equity Incentive Plan.
• Each option has an exercise price of $1.53.
• The options vest 100% on the grant date (December 31, 2025) and are immediately exercisable.
• The options have an expiration date of December 31, 2035.
• Following this transaction, Mr. Chaouki directly beneficially owns 24,633 derivative securities (options).

Sentiment

Score: 6

Explanation: The acquisition of options by a director is generally a positive signal of confidence, but it's a standard compensation event rather than a significant operational or financial announcement. The immediate vesting is a strong positive for the director.

Positives

• A director acquiring options can signal confidence in the company's future prospects.
• The options vest immediately, providing immediate equity exposure to the director.

Negatives

• No immediate cash investment by the director, as the options were granted as compensation rather than purchased outright.

Risks

• The value of the options is tied to the future performance of MAIA Biotechnology's common stock; if the stock price does not exceed the exercise price of $1.53, the options may expire worthless.

Future Outlook

The granting of stock options to a director under an equity incentive plan suggests an ongoing strategy to align management and director incentives with shareholder value creation over the long term, as the options have a 10-year expiration.

Industry Context

This is a standard compensation practice in the biotechnology industry, where equity incentives are often used to attract and retain talent, especially in early-stage companies, by linking personal wealth to company performance.

Comparison to Industry Standards

• Granting stock options to directors is a common practice across various industries, including biotechnology, to incentivize long-term performance and align interests with shareholders.
• The immediate 100% vesting on the grant date is less common than phased vesting schedules but can be seen in some compensation structures, particularly for non-employee directors.
• The exercise price of $1.53 would need to be compared to MAIA's stock price on the grant date (December 31, 2025) to assess if they were granted at-the-money, in-the-money, or out-of-the-money, which is standard practice.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive signal of director confidence; dilution risk if options are exercised and new shares are issued, though this is standard for equity plans.

Next Steps

• Monitor future Form 4 filings for Steven M. Chaouki to track any exercise or sale of these options.
• Observe MAIA Biotechnology's stock price performance relative to the $1.53 exercise price.

Key Dates

Keywords

MAIA Biotechnology, MAIA, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, Form 4, Biotechnology